From 31 May till 4 June 2024: HIGHLIGHTS FROM ASCO – LUNG CANCER

Your direct line with Chicago

The American Society of Clinical Oncology (ASCO) 2024 brings together leading experts in the different fields of cancer from around the world. And, as usual, they gather together in Chicago, USA. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.

Stay tuned, and get ready for an exciting and informative journey!

With the educational support of:

Daily highlights in lung cancer

Highlights on lung cancer 4

Dr Lizza Hendriks, a respiratory oncologist at the Maastricht University Medical Center (Netherlands), highlights four significant presentations on NSCLC from ASCO 2024 relevant to clinical practice.
A noteworthy presentation at

See video »

Highlights on lung cancer 3

Dr Charlotte De Bondt, thoracic oncologist at GZA Hospitals, Antwerp presents her selection of highlights from the rapid oral abstract session on lung cancer. Dr Jonathan Spicer presented a four-year

See video »

Highlights on lung cancer 2

Dr Dieter Stevens, a thoracic oncologist at University Hospitals Gent in Belgium, shares key findings from ASCO2024 on advanced or metastatic NSCLC patients with rare oncogenic alterations.

See video »

Highlights on lung cancer 1

Prof Dr Christophe Dooms, a respiratory oncologist at the University Hospitals Leuven (Belgium), highlights three significant presentations on mNSCLC from ASCO 2024 relevant to clinical practice. The first trial, NRG-LU002,

See video »

In-depth stories about lung cancer

Palliative care (ASCO plenary)

Despite significant advancements in treatments for lung cancer, many patients still face challenging side effects, including anxiety, depression, and overall declines in quality of life. Recognising the need for comprehensive

See video »

CD8 Radiomics

At the ASCO Congress, the results of a study on a non-invasive tool to assess tumour-infiltrating CD8 T cells from contrast-enhanced CTs using AI approaches were presented. This tool shows

See video »

ADAURA TRIAL

The ADAURA trial, which investigated adjuvant osimertinib for patients with resected stage I to III non-small cell lung cancer (NSCLC) with classic EGFR mutations, has provided significant insights into the

See video »

4-year update from CheckMate 816

In the pivotal, phase III CheckMate 816 study, neoadjuvant nivolumab in combination with chemotherapy was shown to significantly improve the pathological complete response rate (pCR) and event-free survival (EFS) in

See video »

ADRIATIC trial (ASCO plenary)

Over the last decades, therapeutic advances for patients with limited-stage small-cell lung cancer (LS-SCLC) have been limited. With the current standard of care (i.e., concurrent chemoradiotherapy [cCRT]), the prognosis for

See video »

LAURA trial (ASCO plenary)

Based on the results of the phase III PACIFIC trial, consolidation therapy with durvalumab has become the standard of care for patients with unresectable stage III NSCLC who did not

See video »

Lung cancer poster selection

Final analysis of the DESTINY-Lung02 trial

The final analysis of the DESTINY-Lung02 trial, a dose-blinded phase 2 randomised controlled trial, compared two dosages of the antibody-drug conjugate trastuzumab deruxtecan in heavily pretreated, biomarker-selected, HER2 mutation-positive, non-small

See video »

Website created by MediMix © 2023 - Privacy Policy